Drug intelligence / Profile preview

paracetamol + tramadol + dimenhydrinate

Development stage: Unknown
Lead developer: Ortho-McNeil Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of three medications: paracetamol (acetaminophen), tramadol, and dimenhydrinate. Paracetamol is a non-opioid analgesic that helps treat mild to moderate pain and fever. Tramadol is an atypical opioid analgesic that works through multiple mechanisms including μ-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake. Dimenhydrinate is an antihistamine and antiemetic used to prevent or treat nausea, vomiting, or dizziness from motion sickness.

Targets

NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on paracetamol + tramadol + dimenhydrinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + tramadol + dimenhydrinate.

Explore the full profile